Authors
Latest:
Multiple Myeloma: Unmet Needs and Future Directions in CareAfter discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.
Latest:
Dr Garfall on Updated Safety Data for Teclistamab in R/R MyelomaAlfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.
Latest:
Dr. Addeo Discusses the Need for Biomarkers in NSCLCAlfredo Addeo, MD, consultant medical oncologist, University Hospital of Geneva, discusses the need for effective biomarkers in non–small cell lung cancer.
Latest:
Dr. McBride on Biosimilar RituximabAli McBride, PharmD, MS, BCOP, discusses the oncology community’s reaction to biosimilars for rituximab (Rituxan).
Latest:
Dr. McBride on the Potential of Biosimilars in OncologyAli McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.
Latest:
Dr. McBride on the Excitement With Oral OncolyticsAli McBride, PharmD, MS, BCPS, clinical coordinator, Hematology/Oncology, secretary, Association of Community Cancer Centers (ACCC), discusses the importance with and excitement of oral oncolytics.
Latest:
"Ultrathin" Bronchoscopy Improves Care for Patients With Lung NodulesTo spare patients from surgery or other unnecessary procedures, Montefiore Einstein Center for Cancer Care developed an advanced method of bronchoscopy that provides peace of mind for individuals with lung nodules. The minimally invasive bronchoscopy provides a very safe method of biopsy, importantly at very early stages when the nodules are relatively small.
Latest:
Small Renal Masses in Elderly Can Be Managed by SurveillanceSmall renal masses identified in elderly patients can be safely managed by surveillance and maintain the same mortality risk as those who undergo surgery, suggesting that surgery could be avoided altogether in many patients.
Latest:
Dr. Mims on FDA Approval of Ivosidenib in Patients With AMLAlice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).
Latest:
Dr. Mims on the Beat AML Master Trial in AMLAlice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).
Latest:
Dr. Shaw on Sequencing Strategies in ALK-Positive NSCLCAlice T. Shaw, MD, PhD, associate professor of medicine at Harvard Medical School, director of Thoracic Oncology and Paula O’Keefe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, discusses sequencing strategies in ALK-positive non–small cell lung cancer (NSCLC).
Latest:
Using QOPI to Improve Quality Within Your Fellowship ProgramThe QOPI program creates a uniform measurement of the quality of care delivered by an oncologist; this affords self-examination and directed improvement of practices.
Latest:
Dr. Ho on Postmastectomy Radiation TherapyAlice Y. Ho, MD, discusses postmastectomy radiation therapy for patients with breast cancer who have undergone breastreconstructive surgery.
Latest:
Dr. Schwark on Microsatellite Instability and Lynch SyndromeAlicia Latham Schwark, MD, medical genetics fellow, Memorial Sloan Kettering Cancer Center, discusses a study exploring microsatellite instability (MSI) and how it relates to Lynch syndrome across all tumor types. The findings were presented at the 2018 ASCO Annual Meeting.
Latest:
Dr. Morgans on the Current Treatment Landscape For mHSPCAlicia Morgans, MD, MPH, discusses current androgen deprivation therapy combinations and the investigation of radiopharmaceutical combinations for metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Moskowitz on the Challenges of Intensifying Treatment in Hodgkin LymphomaAlison J. Moskowitz, MD, discusses the challenges of intensifying treatment in Hodgkin lymphoma.
Latest:
Dr. Sehgal on Key Targetable Alterations in AMLAlison R. Sehgal, MD, discusses key targetable alterations in acute myeloid leukemia.
Latest:
Dr. Sehgal on the Structure and Manufacturing Process of CAR T CellsAlison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.
Latest:
SABCS Interview SeriesThe January issue of OBTN featured highlights from the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). We wrap up our SABCS coverage this month with interviews on denosumab with Alison Stopeck, MD, associate professor of medicine at the University of Arizona and director of the Clinical Breast Cancer Program at the Arizona Cancer Center; oral bisphosphonates with Rowan T.Chlebowski, MD, PhD, professor and chief of the Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center; and adjuvant chemotherapy�induced alopecia with Hugues Bourgeois, MD, Centre Jean Bernard in Lemans, France.
Latest:
Dr. Cohn on Frontline Therapies in Metastatic Pancreatic CancerAllen L. Cohn, MD, medical oncologist, Rocky Mountain Cancer Centers, discusses frontline therapies in metastatic pancreatic cancer.
Latest:
Dr. Lichter on the Importance of the UN Summit on NCDsDr. Allen S. Lichter the chief executive officer of ASCO on the Importance of the UN Summit on NCD
Latest:
Affordable Care Act Positively Affects Stage at DiagnosisMore Stage I cancers were diagnosed after the passage of the Affordable Care Act within five screenable disease types than were diagnosed before ACA implementation.
Latest:
AR Emerges as a Potential Target in Triple-Negative Breast CancerWhereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.
